Former Novartis exec wants to repurpose generic drugs to fight Covid-19
As sweeps the globe, a growing number of efforts are underway to quickly research and develop treatments and vaccines. Yet much of the work is disjointed and widespread access to any medical product is uncertain. One idea, suggested by Costa Rican officials, is for the World Health Organization to create a and collect patent rights, regulatory test data, and other information that could be shared for product development. The notion is , but Paul Fehlner wants to go a step further. The former global head of intellectual property at Novartis — who now works in a similar role at Axcella Health, but also launched a separate startup — now wants to start a public benefit entity to repurpose generic drugs. The nascent plan is to collect research data, submit whatever looks promising to regulators, and permit existing generic manufacturers
You’re reading a preview, subscribe to read more.
Start your free 30 days